Estimated cost of long-term use of Platinib: How much does it cost per year?
Pralsetinib (Pralsetinib) is a highly potent and highly selective RET receptor tyrosine kinase inhibitor, available in the form of oral capsules, each capsule containing 100 mg of the active ingredient. It has excellent performance in the treatment of RET fusion-positive locally advanced or metastatic non-small cell lung cancer, providing a new treatment option for adult patients. With strict approval from multiple regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the National Medical Products Administration, platinib has been successfully launched in many regions around the world.

For the treatment of non-small cell lung cancer, the recommended dose of platinib is 400 mg daily and should be continued until the patient benefits from treatment or develops intolerable side effects. However, the economic burden caused by long-term use of platinib is a matter of great concern to patients and their families.
In fact, the cost of long-term use of platinib for one year varies depending on many factors, including drug source, purchase channel, dosage adjustment, and individual differences among patients. In China, the price of platinib's original drug is often relatively high, with each box selling for RMB 60,000. If calculated based on the consumption of one box per month, the annual cost will be considerable. In overseas markets, especially the generic drug market, the price of platinib may be different. For example, the price of generic drugs in regions such as Laos is relatively low, and each box may cost more than 4,000 yuan. But even so, the cost of long-term use cannot be ignored.
In addition, factors such as market price fluctuations, changes in drug supply, and changes in patients' medication needs may have an impact on the cost of platinib. Therefore, for patients who need to use platinib for a long time, how to reduce the economic burden while ensuring the therapeutic effect is an issue that needs to be seriously considered.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)